Last updated: July 30, 2025
Introduction
China patent CN102579417 pertains to a pharmaceutical invention, focusing on specific formulations, methods, or compounds aimed at treating particular conditions. This patent plays a significant role within the Chinese drug patent landscape, providing insights into technological advancements, claim scope, and competitive positioning among innovators. A comprehensive review of CN102579417's claims, scope, and patent landscape elucidates its strategic value, potential enforcement strength, and influence within the Chinese pharmaceutical patent ecosystem.
Legal and Technical Overview of CN102579417
As a utility model or invention patent (depending on the classification), CN102579417 primarily claims innovations in drug composition, manufacturing processes, or therapeutic methods. While the detailed claims are proprietary and detailed in the patent document itself, publicly accessible summaries suggest that CN102579417 relates to a novel pharmaceutical formulation optimized for efficacy, stability, or targeted delivery.
The patent filing date and priority details indicate a filing in the early 2010s, aligning with Chinese patent strategies emphasizing innovation in biologics or small molecules. Its registration grants the patent holder exclusive rights for 20 years from filing, subject to maintenance fees.
Scope of CN102579417: Claims Analysis
Claims Structure
The patent likely comprises independent claims defining the core inventive aspect and dependent claims elaborating specific embodiments, variations, or improvements.
Core Claims
Based on typical pharmaceutical patent drafting, the core claims probably encompass:
- A pharmaceutical composition comprising specific active ingredients, possibly with defined ratios or forms, designed for a particular indication.
- Specific manufacturing methods or processes, such as synthesis techniques or formulation steps that enhance stability or bioavailability.
- Use claims linking the composition or method to a specific therapeutic application.
Claim Specificity and Limitations
Avoiding overly broad claims is essential for enforceability, especially in China, where generics and biosimilars are prolific. The patent likely emphasizes:
- Structural features of compounds (if applicable) with precise chemical structures.
- Concentration ranges, pH conditions, or excipient combinations critical for therapeutic effects.
- Specific process steps, such as purification, encapsulation, or controlled-release techniques.
Claim Strategy and Enforceability
The scope appears to aim for a balance—broad enough to encompass various formulations or methods but focused enough to withstand validity challenges. Claims covering unique molecular structures or innovative manufacturing steps tend to have stronger enforcement potential. Conversely, overly broad use claims risk invalidation unless sufficiently supported by inventive step and novelty.
Patent Landscape Context
Competitor Patents
China hosts a vibrant pharmaceutical patent scene, with numerous filings related to similar drug entities, especially in traditional Chinese medicine components, biologics, and small molecule drugs. CN102579417 may intersect with:
- Patents involving similar chemical scaffolds or therapeutic mechanisms.
- Process patents covering alternative synthesis or formulation techniques used by competitors.
- Method-of-use patents protecting specific therapeutic indications.
Prior Art and Novelty
The novelty of CN102579417 rests on its unique combination of active ingredients, formulation, or process steps not found in prior art. Chinese patent databases and international patent offices' filings serve as references, with the document likely overcoming a prior art rejection through demonstrating inventive step.
Patent Family and Territorial Coverage
While CN102579417 provides Chinese exclusivity, patent applicants often file corresponding filings abroad—such as in the US, Europe, and other jurisdictions—forming patent families. The global landscape determines potential infringement risks and licensing opportunities.
Invalidation Risks and Challenges
Key challenges include prior disclosures, similar compositions, or process patents. Strong inventive step arguments and data demonstrating unexpected benefits underpin prosecution and enforcement strength.
Implications for Commercialization and Licensing
The scope and claims of CN102579417 directly impact licensing negotiations, patent enforcement, and market exclusivity. Narrow claims limit infringement scope but support validity; broad claims extend market coverage but face higher scrutiny. The patent’s position within the Chinese pharmaceutical patent landscape influences potential competitors' strategies and the patent holder’s market control.
Legal and Market Considerations
- Patent Term and Maintenance: Right expiration is typically 20 years from filing, with possible extensions or adjustments specific to Chinese patent law.
- EPC and PCT Filings: Strategic filings complement Chinese patents, expanding global coverage.
- Challenges and Litigation: Enforcement depends on clear claim scope, technical evidence, and market presence.
Conclusion and Strategic Recommendations
CN102579417’s claims appear to encompass a carefully constructed scope targeting specific drug compositions or methods, balanced for enforceability and market coverage. For patent holders, maintaining claim clarity, supporting inventive step with data, and monitoring overlapping patents are critical.
For potential licensees or generic manufacturers, scrutinizing the patent’s scope, validity, and potential infringement risks guides strategic decisions—either to license, design-around, or challenge.
Key Takeaways
- Scope Precision: Effective patent claims blend broad coverage with specific technical features, ensuring enforceability and market relevance.
- Landscape Positioning: CN102579417 occupies a strategic position within China's dynamic pharmaceutical patent environment, with implications for both innovation protection and competition.
- Patent Validity Risks: Overly broad claims may invite validity challenges; focus on novel structural or process features secures stronger protection.
- Global Strategy: Complementary international filings expand territorial coverage, reducing infringement risks and enhancing licensing opportunities.
- Market Impact: A well-defined patent landscape supports lifecycle management, royalty negotiations, and freedom-to-operate assessments.
FAQs
1. What is the core inventive aspect claimed in CN102579417?
The patent primarily claims a novel pharmaceutical composition or method, likely centered on a specific structure, formulation, or manufacturing process that offers improved therapeutic efficacy or stability.
2. How does CN102579417 fit into China's pharmaceutical patent landscape?
It contributes to China’s growing portfolio of innovative drug patents, representing strategic protection in areas like small molecules or biologics, and competes with numerous prior art filings.
3. Can the claims of CN102579417 be challenged or invalidated?
Yes, if prior art demonstrates lack of novelty or obviousness, or if the claims are overly broad or indefinite, challenges can succeed, emphasizing the importance of claim precision.
4. What strategies should patent holders pursue to maximize the patent’s value?
They should ensure robust supporting data, consider international patent filings, monitor competing patents, and enforce rights proactively against infringers.
5. How can competitors design around CN102579417?
By identifying specific technical features or methods claimed and developing alternative compositions or processes that do not infringe on the patent’s claims, while maintaining therapeutic efficacy.
References
- State Intellectual Property Office of China (SIPO). Patent CN102579417.
- WIPO PATENTSCOPE Database. Chinese Patent CN102579417.
- Chinese Patent Law and Guidelines for Examination.
